HC Wainwright Has Negative Estimate for DWTX FY2025 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Equities research analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Dogwood Therapeutics in a report issued on Monday, November 10th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of ($5.28) for the year, down from their prior forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q4 2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($2.94) EPS and FY2028 earnings at ($3.11) EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Dogwood Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Up 3.4%

Shares of NASDAQ DWTX opened at $5.83 on Wednesday. The business’s 50 day moving average price is $5.73 and its two-hundred day moving average price is $5.22. The company has a market cap of $13.35 million, a PE ratio of -0.23 and a beta of 1.86. Dogwood Therapeutics has a twelve month low of $1.62 and a twelve month high of $29.28.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its earnings results on Thursday, November 6th. The company reported ($8.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($6.97).

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.